Sera Prognostics, Inc. SERA
Institutional shares held
20.3 Million
28.9K
calls
36.8K
puts
Total value of holdings
$61M
$86K
calls
$110K
puts
Market Cap
$88.8M
29,596,900
Shares Out.
Institutional ownership
68.74%
# of Institutions
74
We take great care to ensure that the data presented and summarized in this overview for SERA PROGNOSTICS, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding SERA
View all-
Baker Bros. Advisors LP New York, NY5.43MShares$16.3 Million0.52% of portfolio
-
Ra Capital Management, L.P. Boston, MA3.03MShares$9.1 Million0.43% of portfolio
-
Interwest Venture Management CO2.42MShares$7.25 Million21.78% of portfolio
-
Vivo Capital, LLC Palo Alto, CA1.65MShares$4.95 Million2.79% of portfolio
-
Black Rock Inc. New York, NY1.41MShares$4.23 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.25MShares$3.76 Million0.0% of portfolio
-
Jpmorgan Chase & CO New York, NY776KShares$2.33 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA600KShares$1.8 Million0.0% of portfolio
-
Awm Investment Company, Inc. New York, NY585KShares$1.76 Million0.71% of portfolio
-
Captrust Financial Advisors Raleigh, NC488KShares$1.46 Million0.01% of portfolio
Latest Institutional Activity in SERA
Top Purchases
Top Sells
About SERA
Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
Insider Transactions at SERA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|
Apr 07
2025
|
Mansoor Raza Mirza |
SELL
Open market or private sale
|
Direct |
107
-0.24%
|
$321
$3.35 P/Share
|
|
Mar 20
2025
|
Jeffrey Thomas Elliott |
BUY
Grant, award, or other acquisition
|
Direct |
30,534
+50.0%
|
-
|
|
Mar 07
2025
|
Austin Aerts Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
4,818
-1.53%
|
$19,272
$4.12 P/Share
|
|
Mar 07
2025
|
Zhenya Lindgardt Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
29,722
-3.28%
|
$118,888
$4.12 P/Share
|
|
Mar 07
2025
|
Robert Gardner Harrison Chief Information Officer |
SELL
Open market or private sale
|
Direct |
3,874
-3.08%
|
$15,496
$4.16 P/Share
|
|
Mar 06
2025
|
Zhenya Lindgardt Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
126,920
+12.28%
|
-
|
|
Mar 06
2025
|
Paul Kearney Chief Data Officer |
SELL
Open market or private sale
|
Direct |
1,338
-0.65%
|
$5,352
$4.16 P/Share
|
|
Mar 06
2025
|
Mansoor Raza Mirza |
SELL
Open market or private sale
|
Direct |
99
-0.23%
|
$396
$4.16 P/Share
|
|
Mar 06
2025
|
Austin Aerts Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
540
-0.17%
|
$2,160
$4.16 P/Share
|
|
Mar 06
2025
|
John J. Boniface Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,044
-1.18%
|
$8,176
$4.16 P/Share
|
|
Mar 06
2025
|
Robert Gardner Harrison Chief Information Officer |
SELL
Open market or private sale
|
Direct |
3,251
-2.52%
|
$13,004
$4.16 P/Share
|
|
Mar 06
2025
|
Benjamin Jackson General Counsel |
SELL
Open market or private sale
|
Direct |
2,285
-1.62%
|
$9,140
$4.16 P/Share
|
|
Mar 05
2025
|
Paul Kearney Chief Data Officer |
BUY
Grant, award, or other acquisition
|
Direct |
47,010
+18.64%
|
-
|
|
Mar 05
2025
|
Austin Aerts Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
37,650
+10.67%
|
-
|
|
Mar 05
2025
|
John J. Boniface Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
47,010
+21.38%
|
-
|
|
Mar 05
2025
|
Robert Gardner Harrison Chief Information Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,770
+16.66%
|
-
|
|
Mar 05
2025
|
Benjamin Jackson General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
34,590
+19.72%
|
-
|
|
Feb 13
2025
|
Robert Gardner Harrison Chief Information Officer |
SELL
Open market or private sale
|
Direct |
3,610
-3.38%
|
$14,440
$4.28 P/Share
|
|
Feb 13
2025
|
Benjamin Jackson General Counsel |
SELL
Open market or private sale
|
Direct |
5,915
-5.27%
|
$23,660
$4.58 P/Share
|
|
Feb 12
2025
|
Austin Aerts Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,915
-2.09%
|
$23,660
$4.58 P/Share
|
Last 12 Months Summary
Buy / Acquisition
494K
Shares
From
18
Insiders
| Grant, award, or other acquisition | 447K shares |
|---|---|
| Exercise of conversion of derivative security | 37.5K shares |
| Other acquisition or disposition | 9.01K shares |
Sell / Disposition
1.34M
Shares
From
9
Insiders
| Open market or private sale | 412K shares |
|---|---|
| Other acquisition or disposition | 931K shares |